Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
G1 Therapeutics Inc
(NQ:
GTHX
)
4.425
+0.295 (+7.14%)
Streaming Delayed Price
Updated: 11:54 AM EDT, May 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about G1 Therapeutics Inc
< Previous
1
2
3
4
5
Next >
G1 Therapeutics Announces Pricing of Offering of Common Stock
November 17, 2022
From
G1 Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
November 17, 2022
Via
Benzinga
G1 Therapeutics Announces Proposed Public Offering of Common Stock
November 17, 2022
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics Says Its Lead Candidate May Cut Adverse Events Of Gilead's Breast Cancer Drug
November 02, 2022
Via
Benzinga
G1 Therapeutics: Q3 Earnings Insights
November 02, 2022
G1 Therapeutics (NASDAQ:GTHX) reported its Q3 earnings results on Wednesday, November 2, 2022 at 06:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
G1 Therapeutics Return On Capital Employed Insights
August 10, 2022
Via
Benzinga
G1 Therapeutics: Q2 Earnings Insights
August 03, 2022
G1 Therapeutics (NASDAQ:GTHX) reported its Q2 earnings results on Wednesday, August 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday
November 03, 2022
Gainers Starry Group Holdings, Inc. (NYSE: STRY) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results.
Via
Benzinga
G1 Therapeutics: Q1 Earnings Insights
May 04, 2022
G1 Therapeutics (NASDAQ:GTHX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Analyst Ratings For G1 Therapeutics
November 04, 2021
Analysts have provided the following ratings for G1 Therapeutics (NASDAQ:GTHX
Via
Benzinga
Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Session
November 02, 2022
Gainers Starry Group Holdings, Inc. (NYSE: STRY) gained 56% to $0.2808 after reporting Q3 results.
Via
Benzinga
G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights
November 02, 2022
From
G1 Therapeutics
Via
GlobeNewswire
Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC)
November 02, 2022
- Data Suggest On-Target Effect of Trilaciclib May Reduce Rates of Myelosuppression, Diarrhea, and Potentially Alopecia Associated with Sacituzumab Govitecan-Hziy -
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)
October 10, 2022
From
G1 Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
August 08, 2022
Via
Benzinga
Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday
August 08, 2022
Gainers
Via
Benzinga
Week In Review: WuXi Biologics And WuXi AppTec Plan $2.8 Billion Investment In Singapore Facilities
July 23, 2022
WuXi Biologics and WuXi AppTec announced that each company would invest $1.4 billion over ten years to build R&D and manufacturing facilities in Singapore. Frontera Therapeutics completed a $160...
Via
Talk Markets
12 Health Care Stocks Moving In Thursday's Pre-Market Session
July 14, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
July 13, 2022
Via
Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
March 16, 2022
On Wednesday, 90 companies set new 52-week lows. Areas of Significance In Today's 52-Week Lows: The company with the largest market cap to set a new 52-week low was...
Via
Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
February 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...
Via
Benzinga
G1 Therapeutics: Q4 Earnings Insights
February 23, 2022
G1 Therapeutics (NASDAQ:GTHX) reported its Q4 earnings results on Wednesday, February 23, 2022 at 06:30 AM. Here's what investors need to know about the announcement....
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2021
November 04, 2021
Upgrades According to B. Riley Securities, the prior rating for Monroe Capital Corp (NASDAQ:
Via
Benzinga
G1 Therapeutics, Inc (GTHX) Q3 2021 Earnings Call Transcript
November 03, 2021
GTHX earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Recap: G1 Therapeutics Q3 Earnings
November 03, 2021
G1 Therapeutics (NASDAQ:GTHX) reported its Q3 earnings results on Wednesday, November 3, 2021 at 08:00 AM. Here's what investors need to know about the announcement....
Via
Benzinga
22 Stocks Moving in Friday's Pre-Market Session
October 15, 2021
Gainers LM Funding America, Inc. (NASDAQ: LMFA) rose 39.5% to $4.80 in pre-market trading after declining around 15% on Thursday. The company recently announced it purchased an...
Via
Benzinga
10 Biggest Price Target Changes For Thursday
September 30, 2021
Jefferies raised Perrigo Company plc (NYSE:PRGO) pr...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
September 30, 2021
Upgrades For Cabot Oil & Gas Corp (NYSE:COG),...
Via
Benzinga
Return on Capital Employed Overview: G1 Therapeutics
August 20, 2021
Pulled from Benzinga Pro data G1 Therapeutics (NASDAQ:GTHX) reported Q2 sales of $6.60 million. Earnings fell to a loss of $38.19 million, resulting in a 49.57% decrease from last...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.